Home » Stocks » KOD

Kodiak Sciences Inc. (KOD)

Stock Price: $101.62 USD -0.22 (-0.22%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 5.48B
Revenue (ttm) n/a
Net Income (ttm) -133.10M
Shares Out 51.26M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $101.62
Previous Close $101.84
Change ($) -0.22
Change (%) -0.22%
Day's Open 103.82
Day's Range 99.66 - 103.98
Day's Volume 189,880
52-Week Range 42.97 - 171.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 days ago - Zacks Investment Research

PALO ALTO, Calif., April 21, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to ...

2 weeks ago - PRNewsWire

With the trading day nearing halfway over, the broad markets were somewhat mixed to close out the week.

Other stocks mentioned: JWN, NLSN, PYPL, CATM, CQP, ICPT, MDB ...
1 month ago - 24/7 Wall Street

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

2 months ago - Zacks Investment Research

PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

2 months ago - PRNewsWire

Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer...

2 months ago - Benzinga

PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

2 months ago - PRNewsWire

PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

3 months ago - PRNewsWire

PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

4 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

5 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

5 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

5 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

5 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 12, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

5 months ago - PRNewsWire

PALO ALTO, Calif., Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

5 months ago - PRNewsWire

Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

5 months ago - Zacks Investment Research

PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

5 months ago - PRNewsWire

Biotech companies with IPOs of at least $50 million in the past three years have averaged an increase in share price of more than 42%. Gainers outpaced decliners by a ratio of two to one, according to a...

6 months ago - GuruFocus

VANCOUVER, British Columbia & PALO ALTO, Calif.--(BUSINESS WIRE)---- $KOD #AbCellera--AbCellera and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeutic antibody...

6 months ago - Business Wire

Despite recent run-ups, these two have what takes to keep rising.

Other stocks mentioned: ALGN
6 months ago - The Motley Fool

PALO ALTO, Calif., Oct. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

7 months ago - PRNewsWire

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, CCXI, MCRB, MYOV, NVAX, SRNE
7 months ago - InvestorPlace

  Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.

Other stocks mentioned: KDP, XRX, CAR, GBDC, IGMS
7 months ago - Benzinga

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: CAR, XRX, AXS, BH, JJSF, KMI, RRR
8 months ago - Benzinga

PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc.

8 months ago - PRNewsWire

PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc.

9 months ago - PRNewsWire

PALO ALTO, Calif., July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retin...

9 months ago - PRNewsWire

Kodiak Sciences (KOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Kodiak Sciences

11 months ago - Zacks Investment Research

Kodiak Sciences Inc. (KOD) CEO Victor Perlroth on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

These are the small cap stocks with the best value, fastest growth, and most momentum for May.

Other stocks mentioned: TPH, XBIT
1 year ago - Investopedia

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

Other stocks mentioned: AUPH, ZYME
1 year ago - The Motley Fool

Coronavirus Has Presented A Buying Opportunity In Kodiak Sciences

1 year ago - Seeking Alpha

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.

Other stocks mentioned: GLPG, LGND
1 year ago - Investopedia

Kodiak Sciences Inc’s (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company’s focus on innovation in a dynamic treatment landscape, according to Goldman Sachs.

1 year ago - Benzinga

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfo...

Other stocks mentioned: CDMO, ENDP, IGMS, ILMN, ISEE, MYL, NVCN ...
1 year ago - 24/7 Wall Street

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, DRRX, EVER, ISEE, PRVB ...
1 year ago - The Motley Fool

Kodiak Sciences: Stock That Skyrocketed In December

1 year ago - Seeking Alpha

These stocks have soared 935% or more this year. Can they keep the momentum going?

Other stocks mentioned: AXSM, CNST
1 year ago - The Motley Fool

Here's why these drugmaker stocks are the year's top performers.

Other stocks mentioned: AXSM, CNST
1 year ago - The Motley Fool

Is (KOD) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Does Kodiak Sciences Inc. (KOD) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

Kodiak Sciences Fully Funded And Ready To Potentially Change Wet-AMD Treatment

1 year ago - Seeking Alpha

Helping people stricken with illness can be richly rewarding in more ways than one.

Other stocks mentioned: ARQL, ARWR, EIDX, GH, MEDP, NEO, NVRO ...
1 year ago - The Motley Fool

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?

Other stocks mentioned: AXSM, KRTX
1 year ago - The Motley Fool

As of late, it has definitely been a great time to be an investor in Kodiak Sciences.

1 year ago - Zacks Investment Research

Kodiak Sciences Inc. (KOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 year ago - Zacks Investment Research

These stocks helped lead the markets higher.

Other stocks mentioned: CHK, PCG
1 year ago - The Motley Fool

Momentum continues from the drugmaker's royalty deal announced earlier this week despite a big public stock offering.

1 year ago - The Motley Fool

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage pr... [Read more...]

Industry
Biotechnology
IPO Date
Oct 4, 2018
Stock Exchange
NASDAQ
Ticker Symbol
KOD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 142.80, which is an increase of 40.52% from the latest price.

Price Target
$142.80
(40.52% upside)
Analyst Consensus: Buy